Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Income (2016 - 2025)

Historic Operating Income for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $75.5 million.

  • Ironwood Pharmaceuticals' Operating Income rose 19444.53% to $75.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 2415.39%. This contributed to the annual value of $93.1 million for FY2024, which is 10984.99% up from last year.
  • Ironwood Pharmaceuticals' Operating Income amounted to $75.5 million in Q3 2025, which was up 19444.53% from $45.3 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Operating Income's 5-year high stood at $75.5 million during Q3 2025, with a 5-year trough of -$1.1 billion in Q2 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' median Operating Income value was $45.4 million (recorded in 2021), while the average stood at -$14.6 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Operating Income skyrocketed by 24322.22% in 2021 and then crashed by 204616.66% in 2023.
  • Ironwood Pharmaceuticals' Operating Income (Quarter) stood at $56.6 million in 2021, then increased by 20.8% to $68.4 million in 2022, then plummeted by 45.02% to $37.6 million in 2023, then decreased by 16.22% to $31.5 million in 2024, then surged by 139.7% to $75.5 million in 2025.
  • Its Operating Income stands at $75.5 million for Q3 2025, versus $45.3 million for Q2 2025 and -$29.1 million for Q1 2025.